Product Name: Lyn (505-511) pY508
Product Number: PE-04ANN90
| Size: | 200 µg | Price: | 35.00 | |
| 1 mg | $US | 71.00 | ||
| 5 mg | 153.00 |
Peptide Name: Lyn (505-511) pY508
Product Use: Services as a blocking peptide for use with the Lyn-pY508 rabbit polyclonal antibody (Cat. No.: AB-PK688) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located near the C-terminus of the kinase. Phosphorylation inhibits phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: EGQ-pY-QQQ
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the Lyn-pY508 rabbit polyclonal antibody (Cat. No.: AB-PK688) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located near the C-terminus of the kinase. Phosphorylation inhibits phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: EGQ-pY-QQQ
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1133.07 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Lyn - pY508 phosphosite-specific antibody (Cat. No.: AB-PK688)
Peptide Molecular Mass Calculated: 1133.07 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Lyn - pY508 phosphosite-specific antibody (Cat. No.: AB-PK688)
Scientific Background: Lyn is a protein-tyrosine kinase of the TK group and Src family. It is important in signal transduction from cell surface receptors and in the regulation of innate and adaptive immune responses and other cellular functions. Phosphorylation of T503 inhibits its phosphotransferase activity.This kinase is highly expressed and widely distributed in most tested human tissues. Lyn deficiency is involved in defects in some mast cell functions. It interacts with phosphorylated LIME1 and with CD79A upon BCR activation. Lyn is inhibited by phosphorylation at T503. It interacts with a variety of cell surface receptors on the cytoplasmic side of the plasma membrane. Lyn is biosynthetically transported to the plasma membrane via the Golgi pool of caveolin along the secretory pathway that requires its catalytic domain, but not activity. Lyn is expressed preferentially in B cells and can be bound in the plasma membrane with IgM, where it participates in antigen-mediated signal transduction. Crosslinking of membrane-bound IgM with antibody induces rapid increase in activities of Lyn and Lyn-associated PI 3-kinase. Lyn may be involved in the changes that are related to tumour pathogenesis. It is constitutively phosphorylated and activated in cells of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) patients. Abnormally enhanced expression levels of activation of Lyn signalling can be critical in survival and proliferation of some types of cancers, inclduing breast carcinomas.
© Kinexus Bioinformatics Corporation 2017